Česky
How the irradiation takes place
The Multiscan Radiology Centre Pardubice started operating the radiotherapy department in January 2003 and in March of the same year inaugurated a newly installed linear accelerator equipped with the latest technology for IMRT treatment. It continued to operate the Teragam cobalt irradiator, which was dismantled and replaced by a new linear accelerator in 2008. At the same time, the existing linear accelerator was upgraded. Since 2006, the department has been equipped with a high dose rate brachytherapy (treatment from a short or contact distance) machine. The Wolf - Medizintechnik T-200 X-ray irradiator is used for the treatment of non-cancerous diseases. The department holds a quality certificate from the German company TÜV - Rheinland (quality certificate according to ČSN EN ISO 9001:2016).
9/2019-present - Comprehensive Cancer Centre of the Pardubice Region, Multiscan s.r.o. - Deputy head physician of Radiation Oncology and Head physician of Brachytherapy
2012-2019 - Comprehensive Cancer Centre of the Pardubice Region, Multiscan s.r.o. - physician
2013-present - Hospital of Pardubice Region, a.s./Pardubice Hospital - Department of Clinical and Radiation Oncology - physician
2006-2015 - Regional Hospital Jičín - Department of Radiation Oncology - physician
2012 - Attestation in radiation oncology
2000-2006 - Faculty of Medicine, Charles University in Hradec Králové
1994-1999 - Gymnasium Ivan Olbracht Semily
Hlavka A., Vanasek J., Odrazka K., et al. Tumor bed radiotherapy in women following breast conserving surgery for breast cancer-safety margin with/without image guidance. Oncology Letters. 2018;15(4): 6009-6014
Dolezel M, Slezak P, Odrazka K, Vanasek J, Hlavka A, Ulrych V, Stuk J, Waczulikova I, Hartmann I: Interfraction variation in prostate cancer - analysis of 11726 cone-beam CT. JBUON 2015; 20(4): 1081-1087. ISSN: 1107-0625, online ISSN: 2241-6293
Kolařová I, Vaňásek J, Hlávka A, Štuk J: Perspective on the treatment of brain metastases in patients with HER2-positive breast cancer. Postgraduate medicine 2017; 2/2017; 152-155
Kolářová, I., Vaňásek, J., Odrážka, K., Dušek, L., Šinkorová, Z., Hlávka, A., Štuk, J., Mergancová, J. (2019). Is There a Benefit of HER2-Positive Breast Cancer Subtype Determination in Clinical Practice? Klinicka onkologie: casopis Ceske a Slovenske onkologicke spolecnosti, 32(1), 25-30.
Zamecnik, M., Voltr, L., Stuk, J., Chlumska, A. ( 2008). Krukenberg tumour with yolk sac tumour differentiation. International Journal of Gynecological Pathology, 27(2), 223-228.
